197. S. S. Bahekar, D. B. Shinde; Acta Pharm., 2003, 53, 223-229.f198. O. Nakaguti, N. Shimazaki, M. Shimazaki and M. Nakatuka; Eur. Pat.Appl., Ep- 1986,168, 005 ; Chem. Abstr.,1986, 105. 191118p199. W. Max, B. Murty, E. Peter, W. Klaur; Novartis Pharma., Switz; PCT Int. WO 032003, 63, 871 (Cl.A61K31/505) ; Chem. Abstr., 2003,139, 164802c.200. V. Papesch, E.F. Schroeder; US Pat. 2724559 (1956), Chem. Abstr.,1956, 50,1370.201. N. Tokutake; Brit. Pat. 146836B, Chem. Abstr., 1977, 87, 102370j.202. P. Steilbuck, R. Baltzly and H.M. Hood; J. Org. Chem., 1963, 28, 1983.203. H. M. Hood; Brit. Pat. 1964, 957, 797; Chem. Abstr.,1964, 61, 3122 .204. C. J. Chappel and C. VanSeemann; Prog. Med. Chem.,1963, 3, 89.205. B. G. Ugarkar, J. M. Dare, J. J. Kopcho; J. Med. Chem., 2000, 43, 2883-93.206. R. Kotva and J. Krepelka; Cellect. Czech. Chem. Commun., 1983, 48(l), 1, 13743, 299-303, 304-311; Chem. Abstr., 1983, 98, 160668a-670v.207. C.Jean-Damien, B. David, K. Ronald, G. Julian, Li Pan, D. Robert; VertexPharmaceuticals Incorporated, USA; PCT Int. Appl. WO 02, 2002, 22, 608(Cl.C07D403/12); Chem. Abstr., 2002,136, 247584x.208. B. De'Souza and J.J. Galay; Eur. Pat. 1984, 105, 029 ; Chem. Abstr., 1984, 101,72748b.209. G. W. Anderson, IF.Halverstadt, WH, Miller RO, Rohlin; J. Am. Chem.Soc., 1945,67, 2197.210. Calas, Michele, Pages, Cecile and Barhier, Alain; Eur. J. Med. Chem., Chem.Ther.,1983, 18 (1) (Fr.); Chem. Abstr.,1983, 99, 53686d.211. Guo, Huiyan, Yu. Zhili and Su. Shengmao; Yzoxue Xuebao 18(3), 185-90(Ch.);Chem. Abstr.,1983, 99, 70673r.212. A. Stuart, T. Paterson and B. Roth; J. Med. Chem., 1983, 26 (5), 667-73;Chem.Abstr., 1983, 98, 16066y.213. R. Kotva, J. Krepelka; Czech. C.S., 1984, 224, 239 ; Chem. Abstr., 1985, 102,45974m.214. V. K. Ahuwalia, H.R. Sharma and R. Tyagi; Ind. J. Chem. 1987, 26-B(7), 697-699 ;Chem. Abstr., 1988, 109, 6474y.215. J. M. Parmar, J.J. Modha, A.R. Parikh; Ind. J. Chem. 1999, 38-B, 440-444.216. O. A. Fathlla; Ind. J. Chem., 2001,40(B), 37-42.172References…..
217. L. R. Patil, V.S. Ingle, S.P. Bondge, V.E. Bhingolikar; Ind. J. Het. Chem., 2001,11,131.218. J. M. Parmar, J.J. Modha, A.R. Parikh; J. Inst. Chemist (India); 2001, 73(1).219. D. N. Nagar, K.H. Sikotra and V.H. Shah; J. Inst. Chemist (India); 2001, 73(3), 93.220. D. N. Nagar, K.H. Sikotra and V.H. Shah; J. Inst. Chemist (India); 2001, 73 (4),132.221. H. S. Patel, V.K. Patel, B.C. Dixit; Oriental J. Chem., 2001,17(3), 411-414 .222. N. J. Datta, R.C. Khunt and A.R. Parikh; Oriental J. Chem., 2001, 18 (1), 131-134.223. C. S. Andotra, S. Kaur and J. Khajuria; Ind. J. Het. Chem.,2002, 12 (1), 77-78.224. E. S. Devi, E.O. Prakash, J.T. Rao; J. Inst. Chemist (India); 2002, 74(5), 167.225. B. Kaspar, G. P. Sorana, I. Khalid; Chem. Abstra.,2002, 136, 151176q.226. H. M. F. Madkour, M.A.I. Salem, E.A. Soliman, N.F.H. Mahmoud; PhosphorusSulfur and Silicon and the Related Elements, 2002,170, 15-27. Chem.Abstra.,2002,136,183780y.227. S. Tsuneyuki, H. Toshihide, M. Toru, K. Tsutomu, H. Shinsuke; Ono PharmaceuticCo.Ltd., Japan PCT Int. Appl. WO 02 2002, 51, 815, (Cl.C07D239/47) ; Chem.Abstr.,2002, 137, 78963h.228. E. Martin, Z. Hugo, C. Fredrik, A. Peter; Syngenta participations A. G.;Switz. PCTInt.Appl. WO 02 2002, 53, 560 (Cl. C07D401/04); Chem. Abstra.,2002,137,169533j.229. Z. Chengxin, L. Zheng-Yu, W. George, B. Neal, L. Serge; Motorina, Irina (usa)U.S.Pat. US 2003,114, 445; Chem. Abstr.,2003,137, 53032g.230. L.R. Patil, P.N. Mandhare, S.P. Bondge, S.B. Munde, R.A. Mane; Ind. J. Het.Chem.,2003,12(3), 245-248.231. B.K. Karale, C.H. Gill, M.S. Shinagare; Ind. J. Het. Chem.,2003, 12 (3), 267-270.232. S. N. Swamy, A.K. Murthy, E. Rajanendar; Ind. J. Het. Chem. 2003,12(4), 357-360.233. A. Kumar, P. Sharma, R. Sharma, P. Mohan; Ind. J. Chem.,2003, 42-B, 416-420.234. A. K. Padhy; Ind. J. Chem., 2003, 42-B, 910-915.235. M. Kurono; Jp 62, 267, 272 (1987); Chem. Abstr.,1988,109, 37382t.236. K. Atwal; US 4,1988, 769, 371; Chem. Abstr.,1989, 110, 114853a.237. Chotto and A. Mizuno ; Eur. Pat. Ep. 1988,195, 374 ; Chem. Abstr., 1989,110,231653w.173References…..
- Page 3:
The Sarvodaya Education Society’s
- Page 6 and 7:
selfless help, moral support and gu
- Page 9 and 10:
Introduction and Spectral studies .
- Page 11 and 12:
“STUDIES ON SOME HETEROCYCLICENTI
- Page 13 and 14:
Pyrimidine derivatives have been pr
- Page 15 and 16:
Isoxazole derivative synthesized by
- Page 17 and 18:
“STUDIES ON SOMEHETEROCYCLIC ENTI
- Page 19 and 20:
(b) Pharmacokinetics: It is derived
- Page 21 and 22:
(C) Drug DevelopmentMany natural pr
- Page 23 and 24:
The process of drug design is exten
- Page 25 and 26:
(l) Non steroidal anti-inflammatory
- Page 27 and 28:
INTRODUCTIONThe aza-indolizine cont
- Page 29 and 30:
PHARMACEUTICAL IMPORTANTMuch resear
- Page 31 and 32:
Compd. R 1 R 2 R 3a :- H 7-Me-6,8-B
- Page 33 and 34:
S. Kristjan, Gudmundsson and A. Bra
- Page 35 and 36:
STUDIES ON IMIDAZOPYRIDINE DERIVATI
- Page 37 and 38:
(a) Chalcones with monoethanolamine
- Page 39 and 40:
Das B.P. et al. 111 have found that
- Page 41 and 42:
Furthermore, Alcaraz M.J, et al. 13
- Page 43 and 44:
REACTION SCHEMECl+ClOClOClClCH 3NH
- Page 45 and 46:
Instrument : SHIMADZU FTIR 8400 Spe
- Page 47 and 48:
SignalNo.SignalPosition(δppm)Relat
- Page 49 and 50:
ANTIMICROBIAL ACTIVITYProducts : Ch
- Page 51 and 52:
The reaction mixture was poured on
- Page 53 and 54:
TABLE NO.- 1A BIOLOGICAL SCREENING
- Page 55 and 56:
PART-IISTUDIES ON PYRIMIDINES
- Page 57 and 58:
The self consistent (pi)electron de
- Page 59 and 60:
class of dye viz. trichloro pyrimid
- Page 61 and 62:
ability to cleave nucleic acid targ
- Page 63 and 64:
SSNHNHoONOoONOo(11) (12)oOHThe Pyri
- Page 65 and 66:
called ABPP or bropirimine(2-amino-
- Page 67 and 68:
acid so that it could be utilized f
- Page 69 and 70:
have reported the 5-substitutedfuro
- Page 71 and 72:
maturation of the viral mRNA molecu
- Page 73 and 74:
Nevertheless, these compounds const
- Page 75 and 76:
OHHNCH 3Cl(CH 2 )nSNNR 2R 1N H 2NSR
- Page 77 and 78:
SECTION-ISTUDIES ONOXOPYRIMIDINES
- Page 79 and 80:
PHARMACEUTICAL IMPORTANCEIn recent
- Page 81 and 82:
REACTION SCHEMECH 3NNCHOCl10% KOH R
- Page 83 and 84:
INSTRUMENT :SHIMADZU FTIR 8400 Spec
- Page 85 and 86:
SignalNo.SignalPosition(δppm)Relat
- Page 87 and 88:
EXPERIMENTALSynthesis and therapeut
- Page 89 and 90:
TABLE NO.- 2(IB)PHYSICAL CONSTANTS
- Page 91 and 92:
INTRODUCTIONThiopyrimidine derivati
- Page 93 and 94:
H 3 COHNRH 3 CH 3 CNHS( IV ) R = ar
- Page 95 and 96:
SYNTHESIS AND THERAPEUTIC EVALUATIO
- Page 97 and 98:
IR SPECTRAL STUDIES OF 6-(2-(4-CHLO
- Page 99 and 100:
NMR SPECTRAL STUDIES OF 6-(2-(4-CHL
- Page 101 and 102:
MASS SPECTRAL STUDIES OF 6-(2-(4-CH
- Page 103 and 104:
[F] Antimicrobial activity of 6-(2-
- Page 105 and 106:
SECTION-IIISTUDIES ONAMINOPYRIMIDIN
- Page 107 and 108:
ArCHO+ArCOCH3NaOHMethanolR R 1ONaOH
- Page 109 and 110:
SYNTHESIS AND THERAPEUTIC EVALUATIO
- Page 111 and 112:
IR SPECTRAL STUDIES OF 4-(2-(4-CHLO
- Page 113 and 114:
NMR SPECTRAL STUDIES OF 4-(2-(4-CHL
- Page 115 and 116:
MASS SPECTRAL STUDIES OF 4-(2-(4-CH
- Page 117 and 118:
[F] Antimicrobial activity of 4-(2-
- Page 119 and 120:
PART-IIISTUDIES ONCYCLOHEXENONES
- Page 121 and 122:
2. Michael addition of chalcone wit
- Page 123 and 124:
Rheinheimer J. et al. 381have synth
- Page 125 and 126:
SYNTHESIS AND THERAPEUTIC EVALUATIO
- Page 127 and 128:
IR SPECTRAL STUDIES OF ETHYL-6-(2-(
- Page 129 and 130:
NMR SPECTRAL STUDIES OF ETHYL-6-(2-
- Page 131 and 132:
MASS SPECTRAL STUDIES OF ETHYL-6-(2
- Page 133 and 134:
Antimicrobial testing was carried o
- Page 135 and 136:
PART-IVSTUDIES ON PYRAZOLINES
- Page 137 and 138:
H 2 C= CHCN + Ar - NHNH 2NArN(3) 2
- Page 139 and 140:
PHARMACEUTICAL IMPORTANCE :2- Pyraz
- Page 141 and 142:
Kadu et al. 424 and antimicrobial b
- Page 143 and 144: REACTION SCHEMECH 3NNClCHO10% KOHRO
- Page 145 and 146: Instrument : SHIMADZU FTIR 8400 Spe
- Page 147 and 148: SignalNo.SignalPosition(δppm)Relat
- Page 149 and 150: EXPERIMENTALSynthesis and therapeut
- Page 151 and 152: TABLE NO.- 4(B)PHYSICAL CONSTANTS O
- Page 153 and 154: INTRODUCTION:Isoxazole come under t
- Page 155 and 156: PHARMACEUTICAL IMPORTANCE :Isoxazol
- Page 157 and 158: SYNTHESISAND THERAPEUTIC EVALUATION
- Page 159 and 160: IR SPECTRAL STUDIES OF 2-(4-CHLOROP
- Page 161 and 162: NMR SPECTRAL STUDIES OF 2-(4-CHLORO
- Page 163 and 164: MASS SPECTRAL STUDIES OF 2-(4-CHLOR
- Page 165 and 166: [F]Antimicrobial activity of 2-(4-c
- Page 167 and 168: PART-VISTUDIES ON OXIRANES
- Page 169 and 170: ( iii ) Epoxidation can also been c
- Page 171 and 172: Moreover, Nomura Yutaka et al. 487
- Page 173 and 174: SYNTHESIS AND THERAPEUTIC EVALUATIO
- Page 175 and 176: IR SPECTRAL STUDIES OF (3-(2-(4-CHL
- Page 177 and 178: NMR SPECTRAL STUDIES OF (3-(2-(4-CH
- Page 179 and 180: MASS SPECTRAL STUDIES OF (3-(2-(4-C
- Page 181 and 182: [F] Antimicrobial activity of (3-(2
- Page 184 and 185: 1. J. A. Joule and K. Mills; Hetero
- Page 186 and 187: 37. James J. Kaminski, D. G. perkin
- Page 188 and 189: 78. Ms. B. S. Hastak and B. J. Ghiy
- Page 190 and 191: 116. V. R. Mudalir and V. Joshi ; I
- Page 192 and 193: 150. S. Inoue, A. J. Saggimoto and
- Page 196 and 197: 238. A. Kreutzberger and M. Sellhei
- Page 198 and 199: 280. See, for example, W. H. Prusof
- Page 200 and 201: 326. C. W. Whitehead and J. J. Trav
- Page 202 and 203: 366. Nagarjan K., Shenoy S. J.; Ind
- Page 204 and 205: 396. Ausra Voskiene,Vytautas Mickev
- Page 206 and 207: 432. Solankee Sejal; Prajapati Yoge
- Page 208 and 209: 463. Mishra Ashutosh ; Jain Sanmati
- Page 210 and 211: 496. Kaneko Mashami, Saitoh Yutaka,
- Page 212 and 213: CH 3CH 3NNClNNClORHNONRRRC 6 H 5 -
- Page 214 and 215: CH 3CH 3NNClNNClEtOOCORHNNRRRC 6 H